Literature DB >> 16696579

Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Jiri Horacek1, Vera Bubenikova-Valesova, Milan Kopecek, Tomas Palenicek, Colleen Dockery, Pavel Mohr, Cyril Höschl.   

Abstract

Atypical antipsychotics have greatly enhanced the treatment of schizophrenia. The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained. This article summarises the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiology of schizophrenia.When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant. The optimal occupancy of dopamine D(2) receptors seems to be crucial to balancing efficacy and adverse effects - transient D(2) receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D(2) receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms. Partial D(2) receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D(2) receptors. Balancing presynaptic and postsynaptic D(2) receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D(2) receptors. Serotonergic modulation is associated with a beneficial increase in striatal dopamine release. Effects on the negative and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D(2) and serotonin 5-HT(2A) receptor antagonism (e.g. by olanzapine and risperidone), partial D(2) receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors. In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus. This mechanism may normalise glutamatergic dysfunction and structural abnormalities and affect the core pathophysiological substrates for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696579     DOI: 10.2165/00023210-200620050-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  155 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.

Authors:  M H Chakos; J A Lieberman; J Alvir; R Bilder; M Ashtari
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

3.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.

Authors:  M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

4.  Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesco Bedogni; Massimo Gennarelli; Jorge Perez; Giorgio Racagni; Marco A Riva
Journal:  Neuroreport       Date:  2004-09-15       Impact factor: 1.837

5.  SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.

Authors:  Stefania Bonaccorso; Herbert Y Meltzer; Zhu Li; Jin Dai; Anna R Alboszta; Junji Ichikawa
Journal:  Neuropsychopharmacology       Date:  2002-09       Impact factor: 7.853

6.  Modulatory role of dopamine on excitatory amino acid receptors.

Authors:  O Gandolfi; R Dall'Olio
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1996-05       Impact factor: 5.067

7.  Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.

Authors:  Walid Abi-Saab; John P Seibyl; D Cyril D'Souza; Laurence P Karper; Ralitza Gueorgueva; Anissa Abi-Dargham; Ma-Li Wong; Sachin Rajhans; Joseph P Erdos; George R Heninger; Dennis S Charney; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2002-04-05       Impact factor: 4.530

Review 8.  White matter changes in schizophrenia: evidence for myelin-related dysfunction.

Authors:  Kenneth L Davis; Daniel G Stewart; Joseph I Friedman; Monte Buchsbaum; Philip D Harvey; Patrick R Hof; Joseph Buxbaum; Vahram Haroutunian
Journal:  Arch Gen Psychiatry       Date:  2003-05

Review 9.  Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.

Authors:  Małgorzata Pietraszek
Journal:  Pol J Pharmacol       Date:  2003 Mar-Apr

10.  Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study.

Authors:  L E DeLisi; A L Hoff; J E Schwartz; G W Shields; S N Halthore; S M Gupta; F A Henn; A K Anand
Journal:  Biol Psychiatry       Date:  1991-01-15       Impact factor: 13.382

View more
  119 in total

1.  Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Authors:  A P Rajkumar; B Poonkuzhali; A Kuruvilla; A Srivastava; M Jacob; K S Jacob
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

2.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

3.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

Review 4.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

5.  High precision liquid chromatography analysis of dopaminergic and serotoninergic responses to acute alcohol exposure in zebrafish.

Authors:  Diptendu Chatterjee; Robert Gerlai
Journal:  Behav Brain Res       Date:  2009-06-08       Impact factor: 3.332

Review 6.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 7.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

8.  A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia.

Authors:  Michelle Y Deng; Gráinne M McAlonan; Charlton Cheung; Cindy P Y Chiu; Chi W Law; Vinci Cheung; Pak C Sham; Eric Y H Chen; Siew E Chua
Journal:  Psychopharmacology (Berl)       Date:  2009-07-30       Impact factor: 4.530

9.  Enhancing Completion of Cognitive Processing Therapy for Posttraumatic Stress Disorder with Quetiapine in Veterans with Mild Traumatic Brain Injury: a Case Series.

Authors:  Muhammad R Baig; Jennifer L Wilson; Jennifer A Lemmer; Robert D Beck; Alan L Peterson; John D Roache
Journal:  Psychiatr Q       Date:  2019-06

10.  Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Authors:  J Sloan Manning; Susan L McElroy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.